|Title:|| Quinoline type mevalonolactones|
|Abstract:||Described herein are mevalonolactone derivatives having a quinoline ring of formula (I) ##STR1## wherein the R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, Y and Z variables are described therein.|
|Inventor(s):|| Fujikawa; Yoshihiro (Funabashi, JP), Suzuki; Mikio (Funabashi, JP), Iwasaki; Hiroshi (Funabashi, JP), Sakashita; Mitsuaki (Saitama-ken, JP), Kitahara; Masaki (Saitama-ken, JP) |
|Assignee:|| Nissan Chemical Industries Ltd. (Tokyo, JP) |
1. A pharmaceutical composition for the control or treatment of at least one of hyperlipidemia, hyperlipoproteinemia, and atherosclerosis, comprising an active agent which consists of a
compound of the formula, ##STR16## Z=--CH(OH)--CH.sub.2 --CH(OH)--CH.sub.2 --COO. 1/2Ca in a pharmaceutically effective amount together with a pharmacologically acceptable carrier.
2. The composition of claim 1 wherein said agent is an anti-hyperlipidemia agent.
3. The composition of claim 1, wherein said agent is an anti-hyperlipoproteinemia agent.
4. The composition of claim 1, wherein said agent is an anti-atherosclerosis agent.